Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05626465
Other study ID # 2021-01971
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 2023
Est. completion date February 2028

Study information

Verified date January 2023
Source University Hospital, Geneva
Contact Kim Wiskott, MD
Phone 0041797737424
Email kim.wiskott@hcuge.ch
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of our study is to highlight biomarker-s of Abusive Head Trauma by proteomics analyses on the serum of child victims of abuse.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 174
Est. completion date February 2028
Est. primary completion date February 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 2 Years
Eligibility Inclusion Criteria: - Age : 0-2 y.o - Medical consultation for malaise, seizure (without fever), loss of consciousness, traumatic bain injury, or cranioplasty - Blood test during medical care - Accepted informed consent Exclusion Criteria: - Refused informed consent - For control groups : medical history of child abuse - For AHT group : rare metabolic disease (Menkes, etc..)

Study Design


Intervention

Other:
Blood test
Proteomic analyses on serum

Locations

Country Name City State
France Ginhoux Thiphanie Lyon Rhône
Switzerland Wiskott Kim Geneva

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Geneva Hospices Civils de Lyon

Countries where clinical trial is conducted

France,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Highlight novel biomarker-s of AHT Proteomic analyses will be made on serum of infant victim of AHT. Results will be compare with control groups (traumatic brain injury, cranioplasty, malaise). Hospital admission to discharge (up to 3 days)
See also
  Status Clinical Trial Phase
Completed NCT04608877 - Take 5 + Audio Clip Randomized Control Trial N/A